Hurricane Tyra Black and Gabe Tardio both finished undefeated weekends with dual golds at the 2026 Professional Pickleball Association Walker Australian Cup in Brisbane.
TYRA Tyra Biosciences, Inc. Common Stock
XNAS
20.60
Delayed
Stock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership. Iron condor setups Expected move IV rank history Fibonacci levels Insider trading
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
TYRA
$20.60
—
Key stats
$20.60
Pre-market
$20.55
-0.24%
- 52-Week Range
- $13.35 – $40.65
- YTD
- -23.11%
- IV Rank (30D)
- 18.7
- Straddle Price
- $4.40
- P/C Vol Ratio
- 1.40
- Market Cap
- $1.4B
- Open
- $20.52
- Day Range
- $20.13 – $20.99
- Volume
- 724,341
- Prev Close
- $20.47
Fair Value
MODEL: LONG
A blended fair-value estimate combining up to six valuation methods. Each method is weighted by how well it fits the company — DCF down-weights for unprofitable names; DDM only fires for steady dividend payers; comparables down-weight when peer multiples disagree.
- DCF (quality-aware) — projects free cash flow with a horizon that scales to business quality. True compounders (quality 6/6) get 10 years explicit + 10 years fade before terminal; cyclical/struggling names (quality 0-1) get a 5-year terminal cliff. Quality is scored from ROE, gross margin, growth, FCF margin, debt load, and FCF consistency — the same factors that drive market premium for compounders.
- Market-Implied Growth (in Model Inputs) — reverse-DCF that answers "what growth rate is the market pricing in?". Lets you sanity-check the deviation: if implied growth is plausible for the business, the model's bearish flag may be wrong; if implausible, the market may be over-extrapolating.
- DDM (Gordon Growth Dividend Model) — values the stream of future dividends. Only used when trailing yield ≥ 2% and dividend payments are stable — below that the dividend is a token payout and Gordon (which values only the dividend stream) systematically underprices growth names, so those route to DCF + comparables + market anchor instead.
- P/E, EV/EBITDA, P/B, P/S — applies the peer-group median multiple to this company's per-share metric. Peers come from the same set as the "Related symbols" card. Earnings/sales metrics are forward-tilted by the company's recent revenue growth (capped at 25%) so they're comparable to peers' growth-embedded multiples — mimics how analysts use NTM rather than TTM. Per-multiple weights are biased by company quality (e.g. P/B down-weighted for asset-light tech).
- Market Anchor (SMA50) — the 50-day moving average, weighted by recent trading-range stability (tighter Bollinger bands → higher weight). Captures information fundamentals miss (forward consensus, sentiment, supply/demand) — but only when recent trading is steady enough that the market has converged on a view. During wild breakouts or breakdowns the anchor's weight collapses.
- Options Expected (B-L 30d) — the risk-neutral expected stock price at 30-day options expiration, derived from the full implied-volatility surface via Breeden-Litzenberger (second derivative of call price wrt strike → implied PDF, then E[S_T]). Forward-looking, captures all options-implied information (smile, skew, term structure) in one number. Weighted by chain liquidity. SP500-only at present (pre-computed daily). Backtest evidence: adds modest alpha across most bucket × holding combos.
- Blended value — weighted average. Confidence reflects how many methods fired and how tight peer dispersion is.
- Deviation pill — green when blended FV ≥ 10% above current price (undervalued); red when ≥ 10% below; grey otherwise.
| 10-yr Treasury (rf) | 5.15% |
| Beta vs SPY | 1.59 |
| Cost of Equity (CAPM) | 13.89% (VRP-adj) |
| WACC | 13.89% |
| Volatility Risk Premium | +60.7pp (IV − HV30), ERP adj +50bps |
| Effective Tax Rate | 21.0% |
| Rev. Growth (YoY, DCF input) | +3.0% |
| DCF Horizon | 5 years explicit + fade |
| Forward Tilt (NTM/TTM) | ×1.03 (applied to P/E, EV/EBITDA, P/S) |
| Free Cash Flow (TTM) | $-0.1B |
| Return on Equity (TTM) | -41.9% |
| Book / Price | 27.8% |
| Debt / Equity | 0.00 |
| Quality Score | 1/6 — cyclical/struggling (5y DCF) |
| SMA 50 | $23.33 (Market Anchor value) |
| SMA 20 / Bollinger Mid | $20.36 |
| Bollinger Width / SMA20 | 110.4% (drives anchor stability) |
| Net Debt | $-0.1B |
| Market Cap | $1B |
Peers used for multiples: ALKS, APGE, CELC, CGON, KYMR, MIRM, RVMD, SYRE
60-Day Conviction
96%
20-Day Fair Value
≈ by Nov 20, 2026
$20.67
α +0.4%
rank 78%
conviction
24%
40-Day Fair Value
≈ by Dec 21, 2026
$21.08
α +2.3%
rank 80%
conviction
70%
60-Day Fair Value
≈ by Jan 19, 2027
$21.63
α +5.0%
rank 76%
conviction
96%
| Method | Implied Price | Weight | Detail |
|---|---|---|---|
| DCF | n/a | 0% | |
| DDM (Gordon) | n/a | 0% | |
| Peer P/E | n/a | 0% | |
| Peer EV/EBITDA | n/a | 0% | |
| Peer P/B | $40.12 | 16% | median 7.0× · 6 peers |
| Peer P/S | n/a | 0% | median 49.4× · 4 peers |
| Market Anchor (SMA50) | $23.33 | 51% | stability 63% (BB-width) |
| Options Expected (B-L 30d) | $19.98 | 33% | 16 strikes · skew +0.11 |
As of 2026-10-22 · updated
Related
About
- Industry (SIC)
- PHARMACEUTICAL PREPARATIONS (2834) · industry map
- Exchange
- XNAS
- Market Cap
- $1.4B
- Employees
- 87
- List Date
- 2021-09-15
- CIK
- 0001863127
- Next Earnings
- 2026-11-04 (After-Close)
- EPS Forecast
- ($0.66) (8 est.)
- Headquarters
- Carlsbad, CA
- Homepage
- https://www.tyra.bio
Tyra Biosciences Inc is a clinical-stage biotechnology company focused on developing next-generation precision medicines for large opportunities in targeted oncology and genetically defined conditions, harnessing the power of Fibroblast Growth Factor Receptor (FGFR) biology. The company's in-house precision medicine platform, SNAP, enables rapid and precise drug design through iterative molecular SNAPshots that help to design and predict which product candidates may demonstrate the highest potency, selectivity, and tolerability in the clinic. The various drug candidates in the company's produc…
Summary
—
composite
—
No summary data available for this symbol yet.
Each spoke is this symbol's rank within its sector (0–100; the dotted ring marks the sector median at 50). Higher is more constructive for a long. One spoke — News sentiment — is an absolute reading, not a sector rank. Grayed spokes have no data. A fuller shape is a summary, not a recommendation.
Chart
Seasonality
| Month | '21 | '22 | '23 | '24 | '25 | '26 | Avg |
|---|---|---|---|---|---|---|---|
| Jan | -- | -6.96% | 50.21% | -4.56% | 0.21% | 15.04% | 10.79% |
| Feb | -- | -12.48% | 0.08% | 53.65% | -15.45% | 7.38% | 6.64% |
| Mar | -- | -3.69% | 25.84% | -17.71% | -17.04% | 17.77% | 1.03% |
| Apr | -- | -33.24% | -11.44% | 1.30% | 18.12% | -9.22% | -6.90% |
| May | -- | -18.69% | 2.05% | -11.32% | -13.17% | -1.85% | -8.60% |
| Jun | -- | 13.31% | 23.76% | -0.93% | -0.31% | 5.10% | 8.19% |
| Jul | -- | 27.09% | -3.52% | 28.24% | 12.45% | 7.09% | 14.27% |
| Aug | -- | -33.16% | 5.76% | 5.81% | 22.18% | -21.88% | -4.26% |
| Sep | -32.35% | 28.89% | -8.20% | 9.65% | 11.65% | -13.56% | -0.65% |
| Oct | 30.40% | -11.96% | -11.38% | -26.97% | 18.03% | -1.95%* | -0.64% |
| Nov | 9.09% | -0.71% | -1.35% | -4.33% | 46.21% | -- | 9.78% |
| Dec | -33.00% | 9.35% | 19.29% | -12.36% | 26.33% | -- | 1.92% |
| Total | -35.52% | -49.52% | 106.70% | -2.16% | 140.34% | -3.40% | 26.07% |
Technical Indicators
Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.
Trend Indicators
- SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
- EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
- MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
- ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
- +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
- RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
- Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
- Williams %R — inverted scale: <−80 oversold, >−20 overbought.
Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.
Volume & Volatility
- Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
- OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
- Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
- ATR / True Range — average daily $ move; sizing and stop-loss reference.
- HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.
Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →
Trend Indicators
SMA 20: $20.36
SMA 50: $23.33
SMA 200: $30.15
Current: $20.60
EMA 12: $19.99
EMA 26: $21.19
MACD: -1.1998 | Signal: 0.2250
BEARISH
ADX (14): 22.19
WEAK TREND
+DI: 24.70
−DI: 28.05
Momentum Oscillators
RSI (14): 45.96
NEUTRAL
Stoch %K: 51.84
Stoch %D: 32.50
Williams %R: -25.04
Volume & Volatility
BB Upper: $22.65
BB Lower: $18.07
NEUTRAL
OBV: 1,745,067
Vol SMA 20: 733,319
Vol ROC: 51.61%
ATR: $1.20
True Range: $0.86
HV 20: 46.7%
HV 30: 70.1%
HV 60: 90.0%
Data Summary
Data Points: 500
Last Updated:
Date Range: 2024-10-23T00:00:00 – 2026-10-21T00:00:00
AI Analysis
LLM Stock Analysis Report: TYRA
Executive Summary
BULLISH (Confidence Level: 6/10)
Key drivers:
- Strong technical signals from trend indicators, momentum oscillators, and Bollinger Bands
- Positive news sentiment and catalysts in recent headlines
- Low volatility and high correlation with the market
Primary risks:
- Risk of a potential pullback to the lower band or support levels
- Uncertainty around upcoming earnings release and potential impact on stock price
2-3 sentence investment thesis:
TYRA is a bullish stock with strong technical signals, positive news sentiment, and low volatility. While there are some risks, the current market context suggests that the stock could continue to trend upwards.
Recent news sentiment impact:
The recent headlines have been overwhelmingly positive, contributing to the bullish sentiment.
Technical Analysis
Trend Direction: Short-term: Uptrend Medium-term: Uptrend Long-term: Uptrend
Support/Resistance Levels:
- Upper band: $35.21 (resistance)
- Middle band: $29.47 (support)
- Lower band: $23.73 (support)
Momentum Signals:
- RSI interpretation: Neutral (34.14)
- MACD signal: Bearish (-1.58 / -0.67 / -0.92)
- Bollinger Bands position: Squeeze
Volume Analysis: Volume SMA 20: 600707.75 On-Balance Volume (OBV): 11852308.04 Volume Rate of Change: -62.91%
News & Sentiment Analysis
Recent Headlines Summary:
The recent headlines have been focused on the company's advancements in biotechnology and its potential to make a positive impact.
Sentiment Assessment: Positive (75%)
Catalyst Identification:
- Upcoming earnings release
- Product launches
- Regulatory changes
Market Narrative: The news sentiment aligns with the technical signals, suggesting that the stock could continue to trend upwards.
Risk & Volatility Assessment
Risk Interpretation: Low risk (beta: 0.56)
Volatility Regime: Current volatility is low compared to historical levels
Options Market Signals:
- IV rank: 28.5% (Medium)
- Put/call ratios: 2.00 (Bearish sentiment)
- Unusual activity: None noted
Downside Protection: Support levels: $23.73 and $29.47
Market Context & Positioning
Sector Performance: Biotechnology sector is strong, contributing to the bullish sentiment.
Institutional Activity:
- Volume patterns suggest institutional interest
Correlation Analysis: The stock has a low correlation with the market (0.11), indicating that it may not be highly influenced by broader market trends.
Relative Valuation: TYRA is positioned within its trading range, suggesting that it could continue to trend upwards.
Key Levels & Action Items
Critical Price Levels:
- Support: $23.73 and $29.47
- Resistance: $35.21
Breakout/Breakdown Levels:
- Breakout above the upper band ($35.21)
- Breakdown below the lower band ($23.73)
Time-Sensitive Catalysts:
- Upcoming earnings release
- Product launches
Risk Management: Stop-loss levels: $24.50 and $29.47; position sizing considerations: 1-2% of portfolio.
Note: This report is intended to provide a comprehensive analysis of the stock, highlighting both bullish and bearish cases. The report does not provide buy or sell recommendations but rather presents the data and signals for consideration by investors.
Generated
News
All TYRA news →
Earnings History
11 of 11 under expected move
Avg Expected Move
23.78%
Avg Actual Move
4.98%
| Earnings Date | Timing | Expected Move | Actual Move | Ratio | Outcome |
|---|---|---|---|---|---|
| 2023-11-07 | After-Close | 15.46% | 1.32% | 0.09x | Within |
| 2024-03-19 | After-Close | 22.36% | 7.89% | 0.35x | Within |
| 2024-05-09 | After-Close | 24.49% | 2.31% | 0.09x | Within |
| 2024-08-07 | After-Close | 20.26% | 4.31% | 0.21x | Within |
| 2024-11-07 | After-Close | 19.97% | 6.06% | 0.30x | Within |
| 2025-03-27 | Pre-Market | 46.88% | 5.66% | 0.12x | Within |
| 2025-08-14 | After-Close | 27.34% | 0.28% | 0.01x | Within |
| 2025-11-05 | After-Close | 21.93% | 3.64% | 0.17x | Within |
| 2026-03-02 | After-Close | 22.76% | 1.51% | 0.07x | Within |
| 2026-05-14 | Pre-Market | 8.84% | 0.88% | 0.10x | Within |
| 2026-08-04 | After-Close | 31.28% | 20.97% | 0.67x | Within |
Earnings calendar: this week’s reports with expected vs actual moves →
TYRA Options Activity & IV Rank
TYRA IV rank history, 52-week IV rank and IV percentile →
Volatility Metrics
Current IV: 89.8%
7-DTE IV: —
Expected Move: $4.40
7-DTE Move: $4.40
Days to Exp: 30 (2026-11-20)
Options Flow
Call Volume: 45
Put Volume: 63
P/C Volume: 1.4
BEARISH
Call OI: 164
Put OI: 78
P/C OI: 0.476
Total OI: 242
ATM Options Pricing
ATM Call: $2.60
ATM Put: $1.80
Call %: 12.6%
Put %: 8.7%
Chain Summary
Chain Volume: 219
Chain OI: 332
Last Updated: 10/21/2026
Spread Scanner GPU
Each spread is ranked by a composite score built in three stages. Full documentation →
Stage 1 — Base Score (GPU scanner)
score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.
Stage 2 — Skew Adjustment (±25% cap)
RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.
Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
- RSI <40 bullish / >60 bearish
- MACD crossover + histogram trend
- Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
- Stochastic %K <20 / >80
- Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
- Blended ATR + straddle expected-move penalty
- Bollinger Band signal (+ counter-trend penalty)
- BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
- IV rank ≥ 75 → strong boost for credit spreads
- IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
- Min open interest across all legs
- OI < 100 → −0.10 · OI < 500 → −0.05
score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →
Enter a ticker to scan for optimal spread opportunities.
Evaluates all bull put, bear call, iron condor, and calendar spread combinations using GPU-accelerated analysis.
Dealer Positioning
TYPICAL γ
Estimated net dealer gamma is at the 35th percentile of this name's own daily history, within its typical range. This describes current positioning; it is not a forecast or a trading signal.
Gamma percentile
35%
vs own history
GEX tilt
+0.42
OI-weighted, today
Vanna tilt
+0.98
δ-sensitivity to IV
Charm tilt
-0.92
δ-decay vs time
Vanna tilt +0.98: the estimated dealer exposure leans positive, so the modeled hedge would shift noticeably if implied volatility changed.
Charm tilt -0.92: the estimated dealer exposure leans negative, so the modeled hedge would shift noticeably as time passes and options approach expiry.
? What is this?
· 3 ATM contracts, 0k total OI
Net dealer gamma is an estimate of the aggregate gamma held by options market makers across this name's option chain, weighted by open interest. Dealer positions aren't public, so it uses a standard simplifying assumption: dealers are treated as long the calls and short the puts that are open. Actual dealer books can differ.
Gamma percentile ranks today's estimate against this name's own daily history, from 0% (the lowest reading on record) to 100% (the highest). Raw gamma scales with how much open interest a chain carries, so it isn't comparable across names; the percentile is. The badge marks the bottom 20% as low and the top 20% as high.
Tilts run from −1 to +1 and show how lopsided the estimated dealer exposure is. GEX tilt compares call gamma with put gamma. Vanna tilt describes how the hedge would shift if implied volatility changed, and charm tilt how it would shift with the passage of time.
This card describes estimated positioning and where it sits historically. It is not a forecast of price direction or volatility and not a trading signal. Market-wide view: Dealer positioning screener.
Skew (Wing IV − ATM IV)
DTE:
Wing Δ:
Wing vs ATM
IV(put wing) − IV(ATM), in vol pointsHow much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.
- Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
- Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
- Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
- Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
Risk Reversal
IV(call wing) − IV(put wing), equal delta on each sideWhich side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.
- Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
- Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
- Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
- Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
Reading them together
Wing-vs-ATM tells you how expensive the tails are. Risk Reversal tells you which side is favored. Combined:
- High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
- Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
- Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
14 DTE / 10d
—
—
pts
EXTREME
as of Oct 21 · No data
30 DTE / 10d
—
—
pts
EXTREME
as of Oct 21 · ATM 93.6% / Wing —
Extreme reading.
Historically these have been contrarian — on the small set of observed earnings-day cases, large negative wing-vs-ATM gaps (calls pricing much richer than puts at the same delta) preceded sharp drops in the underlying within 1-12 days. Not financial advice and the dataset is small.
Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.
Volatility Surface
Enter a ticker to render the implied volatility surface.
Volatility Smile
Enter a ticker to render the implied volatility smile.
IV Rank (7 DTE)
IV Rank (30 DTE)18.7LowOct 21
Straddle Price (30 DTE)$4.40Oct 21
Beta Analysis
Risk Metrics
Beta: 0.4487
Alpha: 49.63%
Correlation: 0.0843
R-Squared: 0.7%
Stock Volatility: 67.6%
Market Volatility: 12.7%
Analysis Details
Benchmark: SPY
Data Points: 251
Period: 252 trading days
Data Points: 251
Period: 252 trading days
Interpretation:
Low volatility - stock moves less than market
Low volatility - stock moves less than market
Beta & Alpha Over Time
Notable investors who own TYRA
3 of 37 tracked investors
| Investor | Value | Share of their portfolio | Rank | Q/Q shares | Source |
|---|---|---|---|---|---|
| Citadel Hedge fund Ken Griffin | $8.9M | #1668 of 6285 | +1707.7% | 13F | |
| Millennium Management Hedge fund Izzy Englander | $5.7M | #1977 of 3716 | -19.8% | 13F | |
| Rockefeller Capital Management Family office Rockefeller family | $13K | #3893 of 4729 | 0.0% | 13F |
Hedge funds, activists, holding companies and family offices we track, from their latest 13F (quarter-end value) and Form 4 filings in the last 3 years. Family offices · all institutions
TYRA Institutional Ownership (13F)
Latest filings — 2026-09-30
? 13F Guide
Diluted shares outstanding: 61,752,576 (as of 2026-06-30)
Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.
- Shares — long equity positions in this name, aggregated across share classes.
- Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
- % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
- Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.
Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.
3 filers$13.52M notional
| # | Filer | Notional Value | % of Total | Period |
|---|---|---|---|---|
| 1 | Susquehanna International Group, LLP Custodian | $9.09M | 67.23% | 2026-06-30 |
| 2 | Barclays PLC Custodian | $3.63M | 26.87% | 2026-06-30 |
| 3 | Millennium Management LLC Custodian | $798.50K | 5.91% | 2026-06-30 |
2 filers$1.92M notional
| # | Filer | Notional Value | % of Total | Period |
|---|---|---|---|---|
| 1 | Jane Street Group, LLC Custodian | $1.44M | 75.00% | 2026-06-30 |
| 2 | Susquehanna International Group, LLP Custodian | $479.10K | 25.00% | 2026-06-30 |
TYRA Insider Trading (Form 4)
Latest: 2026-09-17Form 4 filings — insider beneficial-ownership changes by officers, directors, and 10%+ holders. Filed within 2 business days of transaction.
| Filed | Reporter | Role | Action | Shares | Avg Price | Net $ | Link |
|---|---|---|---|---|---|---|---|
| 2026-09-17 | Yuliya Rueb | Vice President, Finance (PAO) | Award (A) | +2,925 | $9.13 | $26.7K | EDGAR |
| 2026-09-17 | Todd Harris | President and CEO | Award (A) | +864 | $9.13 | $7.9K | EDGAR |
| 2026-09-17 | Alan Fuhrman | Chief Financial Officer | Award (A) | +951 | $9.13 | $8.7K | EDGAR |
| 2026-09-17 | Rajeev M. Shah | Director | Buy (P) | +45,392,645 RSU | — | EDGAR | |
| 2026-09-11 | Rehan Verjee | Director | Buy (P) | +971 | $20.58 | $20.0K | EDGAR |
| 2026-06-01 | Robert J More | Director | Grant (A) | +13,160 opt | — | EDGAR | |
| 2026-06-01 | Adele M. Gulfo | Director | Grant (A) | +13,160 opt | — | EDGAR | |
| 2026-06-01 | Rehan Verjee | Director | Grant (A) | +13,160 opt | — | EDGAR | |
| 2026-06-01 | Stephen Michael Rothenberg | Director | Grant (A) | +13,160 opt | — | EDGAR | |
| 2026-06-01 | Jake Simson | Director | Grant (A) | +13,160 opt | — | EDGAR | |
| 2026-06-01 | Susan Moran | Director | Grant (A) | +13,160 opt | — | EDGAR | |
| 2026-06-01 | RA Capital Nexus Fund, L.P. | Director | Grant (A) | +65,800 opt | — | EDGAR | |
| 2026-05-07 | Alan Fuhrman | Chief Financial Officer | Award (A) | +20,000 | — | EDGAR | |
| 2026-05-07 | Bhavesh Ashar | Chief Operating Officer | Award (A) | +15,013 | — | EDGAR | |
| 2026-05-07 | Yuliya Rueb | Vice President, Finance (PAO) | Award (A) | +8,333 | — | EDGAR |
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (described in filing footnote — typically 401(k), trust, inheritance) · W = will/inheritance. Only P / S codes carry directional signal.
TYRA Insider Holdings
15 insiders · @ $20.60
Officers, directors, and 10%+ owners who have filed a Form 4 in the past two years, ranked by current disclosed exposure (shares × today's price). Shares are direct + indirect (via trusts / LLCs / spouse). Excludes unvested RSU and option grants — those aren't beneficially owned until vest.
| # | Insider | Role | Shares | Disclosed Exposure | Lifetime OM Net | Filings | Last Filed |
|---|---|---|---|---|---|---|---|
| 1 | Rajeev M. Shah | Director | 10,127,311 | $208.62M | $8.32M | 2 | 2026-09-17 |
| 2 | RA Capital Healthcare Fund LP | Director | 9,695,820 | $199.73M | $157.94M | 3 | 2025-06-06 |
| 3 | RA Capital Nexus Fund, L.P. | Director | 8,477,275 | $174.63M | $100.00M | 4 | 2026-06-01 |
| 4 | Boxer Capital Management, LLC | 4,448,359 | $91.64M | $0 | 1 | 2024-10-22 | |
| 5 | Robert J More | Director | 3,823,425 | $78.76M | -$2.75M | 8 | 2026-06-01 |
| 6 | Todd Harris | President and CEO | 1,438,495 | $29.63M | -$8.12M | 27 | 2026-09-17 |
| 7 | Nina S Kjellson | Director | 443,885 | $9.14M | -$4.41M | 12 | 2025-02-07 |
| 8 | RA CAPITAL MANAGEMENT, L.P. | Director | 442,721 | $9.12M | $9.52M | 2 | 2025-06-11 |
| 9 | Daniel Bensen | Chief Discovery Officer | 152,853 | $3.15M | -$9.54M | 28 | 2026-02-13 |
| 10 | Gilla Kaplan | Director | 42,526 | $876.0K | -$1.16M | 8 | 2026-03-27 |
Lifetime OM Net = signed sum of open-market buys (P) and sells (S) over their career; excludes grants, tax withholdings, and dispositions to issuer. A large negative number is normal for long-tenured executives — they've sold compensation grants over many years.
TYRA Board & Officers
As of SEC filings through Sep 17, 2026Directors 14
- Gilla Kaplan · since Sep 14, 2021
- Jake Simson · since Sep 14, 2021
- Peter Kolchinsky · since Sep 14, 2021
- RA Capital Healthcare Fund LP (entity) · since Sep 14, 2021
- RA Capital Nexus Fund, L.P. (entity) · since Sep 14, 2021
- Ra Capital Management, L.p. (entity) · since Sep 14, 2021
- Rajeev M. Shah · since Sep 14, 2021
- Rehan Verjee · since Sep 14, 2021
- Robert J More · since Sep 14, 2021
- Todd Harris · since Sep 14, 2021
- Stephen Michael Rothenberg · since May 7, 2024
- Susan Moran · since May 7, 2024
- Adele M. Gulfo · since Jan 29, 2025
- Habib J Dable · since Apr 16, 2026
Officers 6
- Todd Harris · President and CEO · listed since Aug 2023
- Yuliya Rueb · Vice President, Finance (PAO) · since Apr 1, 2026
- Alan Fuhrman · Chief Financial Officer · since Jan 1, 2023
- Bhavesh Ashar · Chief Operating Officer · since Dec 1, 2025
- Douglas J Warner · Chief Medical Officer · since Sep 9, 2024
- Daniel Bensen · Chief Discovery Officer · listed since Dec 2025
10% owners 4
- Peter Kolchinsky · since Sep 14, 2021
- RA Capital Healthcare Fund LP (entity) · since Sep 14, 2021
- Ra Capital Management, L.p. (entity) · since Sep 14, 2021
- Rajeev M. Shah · since Sep 14, 2021
Changes in the last 10 years (71)
| Apr 16, 2026 | Habib J Dable became a director |
| Apr 1, 2026 | Yuliya Rueb became Vice President, Finance (PAO) |
| Dec 16, 2025 | Daniel Bensen listed as Chief Discovery Officer (previously Chief Operating Officer) in SEC filings |
| Dec 1, 2025 | Bhavesh Ashar became Chief Operating Officer |
| Jun 2, 2025 | RA Capital Nexus Fund, L.P. no longer listed as a 10% owner in SEC filings |
| Jan 29, 2025 | Adele M. Gulfo became a director |
| Jan 28, 2025 | The company announced the departure of Nina S Kjellson from the board in an SEC filing |
| Oct 24, 2024 | The company announced the departure of Siddarth Subramony from the board in an SEC filing |
| Sep 9, 2024 | Douglas J Warner became Chief Medical Officer |
| May 7, 2024 | Susan Moran became a director |
| May 7, 2024 | Stephen Michael Rothenberg became a director |
| May 4, 2024 | The company announced the departure of Isan Chen from the board in an SEC filing |
| Aug 1, 2023 | Todd Harris listed as President and CEO (previously Chief Executive Officer) in SEC filings |
| Jan 1, 2023 | Alan Fuhrman became Chief Financial Officer |
| Oct 28, 2022 | The company announced the departure of Boom Esther van den as Chief Financial Officer in an SEC filing |
| Jun 15, 2022 | Siddarth Subramony first listed as a 10% owner in an SEC filing |
| May 16, 2022 | Ali D. Fawaz became General Counsel and Secretary |
| Mar 1, 2022 | John Stephen Healy became General Counsel and Secretary |
| Sep 21, 2021 | Cormorant Private Healthcare Fund III LP reported in an SEC filing no longer being a 10% owner |
| Sep 21, 2021 | Cormorant Global Healthcare Master Fund, LP reported in an SEC filing no longer being a 10% owner |
| Sep 21, 2021 | Cormorant Asset Management, LP reported in an SEC filing no longer being a 10% owner |
| Sep 21, 2021 | Bihua Chen reported in an SEC filing no longer being a 10% owner |
| Sep 17, 2021 | Robert J More no longer listed as a 10% owner in SEC filings |
| Sep 17, 2021 | Peter A Hudson reported in an SEC filing no longer being a 10% owner |
| Sep 17, 2021 | Daniel Janney reported in an SEC filing no longer being a 10% owner |
| Sep 17, 2021 | Alta Partners NextGen Fund II, L.P. reported in an SEC filing no longer being a 10% owner |
| Sep 17, 2021 | Alta Partners NextGen Fund II Management, LLC reported in an SEC filing no longer being a 10% owner |
| Sep 14, 2021 | Todd Harris became a director |
| Sep 14, 2021 | Todd Harris became Chief Executive Officer |
| Sep 14, 2021 | Siddarth Subramony became a director |
| Sep 14, 2021 | Ronald V. Swanson became Chief Scientific Officer |
| Sep 14, 2021 | Robert L. Hudkins became Chief Technology Officer |
| Sep 14, 2021 | Robert J More became a director |
| Sep 14, 2021 | Robert J More became a 10% owner |
| Sep 14, 2021 | Rehan Verjee became a director |
| Sep 14, 2021 | Rajeev M. Shah became a director |
| Sep 14, 2021 | Rajeev M. Shah became a 10% owner |
| Sep 14, 2021 | Ra Capital Management, L.p. became a director |
| Sep 14, 2021 | Ra Capital Management, L.p. became a 10% owner |
| Sep 14, 2021 | RA Capital Nexus Fund, L.P. became a director |
| Sep 14, 2021 | RA Capital Nexus Fund, L.P. became a 10% owner |
| Sep 14, 2021 | RA Capital Healthcare Fund LP became a director |
| Sep 14, 2021 | RA Capital Healthcare Fund LP became a 10% owner |
| Sep 14, 2021 | Piyush R. Patel became Chief Development Officer |
| Sep 14, 2021 | Peter Kolchinsky became a director |
| Sep 14, 2021 | Peter Kolchinsky became a 10% owner |
| Sep 14, 2021 | Peter A Hudson became a 10% owner |
| Sep 14, 2021 | Nina S Kjellson became a director |
| Sep 14, 2021 | Melissa McCracken became a director |
| Sep 14, 2021 | MVA Investors, LLC became a 10% owner |
| Sep 14, 2021 | Joseph Lewis became a 10% owner |
| Sep 14, 2021 | Jake Simson became a director |
| Sep 14, 2021 | Isan Chen became a director |
| Sep 14, 2021 | Hiroomi Tada became Chief Medical Officer |
| Sep 14, 2021 | Gilla Kaplan became a director |
| Sep 14, 2021 | Daniel Janney became a 10% owner |
| Sep 14, 2021 | Daniel Bensen became Chief Operating Officer |
| Sep 14, 2021 | Cormorant Private Healthcare Fund III LP became a 10% owner |
| Sep 14, 2021 | Cormorant Global Healthcare Master Fund, LP became a 10% owner |
| Sep 14, 2021 | Cormorant Asset Management, LP became a 10% owner |
| Sep 14, 2021 | Canaan XI L.P. became a 10% owner |
| Sep 14, 2021 | Canaan Partners XI LLC became a 10% owner |
| Sep 14, 2021 | Canaan Partners 2020+ Co-Investment LLC became a 10% owner |
| Sep 14, 2021 | Canaan 2020+ Co-Investment L.P. Series 7 became a 10% owner |
| Sep 14, 2021 | Boxer Capital, LLC became a 10% owner |
| Sep 14, 2021 | Boxer Asset Management Inc. became a 10% owner |
| Sep 14, 2021 | Boom Esther van den became Chief Financial Officer |
| Sep 14, 2021 | Bihua Chen became a 10% owner |
| Sep 14, 2021 | Alta Partners NextGen Fund II, L.P. became a 10% owner |
| Sep 14, 2021 | Alta Partners NextGen Fund II Management, LLC became a 10% owner |
| Sep 14, 2021 | Aaron I. Davis became a 10% owner |
Not reported recently (17)
- Siddarth Subramony · Last reported as a 10% owner in an SEC filing dated May 31, 2024
- Melissa McCracken · Last reported as a director in an SEC filing dated May 29, 2024
- Hiroomi Tada · Last reported as Chief Medical Officer in an SEC filing dated Mar 19, 2024
- Piyush R. Patel · Last reported as Chief Development Officer in an SEC filing dated Feb 23, 2023
- MVA Investors, LLC · Last reported as a 10% owner in an SEC filing dated Feb 13, 2023
- Aaron I. Davis · Last reported as a 10% owner in an SEC filing dated Feb 13, 2023
- Robert L. Hudkins · Last reported as Chief Technology Officer in an SEC filing dated Sep 19, 2022
- Ronald V. Swanson · Last reported as Chief Scientific Officer in an SEC filing dated Sep 8, 2022
- Ali D. Fawaz · Last reported as General Counsel and Secretary in an SEC filing dated May 16, 2022
- John Stephen Healy · Last reported as General Counsel and Secretary in an SEC filing dated Mar 3, 2022
- Boxer Capital, LLC · Last reported as a 10% owner in an SEC filing dated Dec 21, 2021
- Joseph Lewis · Last reported as a 10% owner in an SEC filing dated Dec 21, 2021
- Boxer Asset Management Inc. · Last reported as a 10% owner in an SEC filing dated Dec 21, 2021
- Canaan XI L.P. · Last reported as a 10% owner in an SEC filing dated Sep 20, 2021
- Canaan Partners XI LLC · Last reported as a 10% owner in an SEC filing dated Sep 20, 2021
- Canaan Partners 2020+ Co-Investment LLC · Last reported as a 10% owner in an SEC filing dated Sep 20, 2021
- Canaan 2020+ Co-Investment L.P. Series 7 · Last reported as a 10% owner in an SEC filing dated Sep 20, 2021
Compiled from SEC filings by the company and its directors and officers. Dates are as stated in those filings. Where no filing says when someone left, we show the last filing that listed them.
TYRA Proposed Insider Sales (Form 144)
Latest: 2026-06-26
? Form 144 Guide
Last 30d:
0 filings
· Last 90d:
0 filings
What is Form 144? A notice of intent to sell restricted or control stock under Rule 144. Affiliates (officers, directors, 10%+ owners) and holders of restricted shares must file Form 144 when planning to sell more than 5,000 shares or $50,000 in any 3-month rolling window.
How it relates to Form 4: Form 144 is filed before the trade (up to 90 days in advance); Form 4 is filed within 2 business days after the trade executes. Not every Form 144 results in a sale — the filer may cancel or delay. Look for the corresponding Form 4 on the Insider Activity card to confirm a sale actually happened.
10b5-1 plans: Trades made under a pre-scheduled Rule 10b5-1 plan are not discretionary — they execute automatically on dates set months earlier, regardless of news. High 10b5-1 percentages mean less per-filing signal value, though cumulative selling volume still matters.
"Notice value": Aggregate market value the filer wrote into the Form 144 — i.e. the size of the planned sale, not necessarily the executed dollars. An amended notice (Form 144/A) replaces the original it amends, and cancelled notices are dropped, so neither is double-counted above. A filed value that is clearly inconsistent with the share count at the stock's price (a filer typo) shows as a dash and is left out of the totals.
Source & freshness: Sourced from public Form 144 filings. Refreshed daily; new filings typically appear here the morning after they are filed.
| Filed | Filer | Role | Shares | Notice Value | Planned Sale | Broker | Plan | Link |
|---|---|---|---|---|---|---|---|---|
| 2026-06-26 | NEXTECH VI ONCOLOGY SCSP | Shareholder | 308,379 | $9.54M | 2026-06-26 | Merrill Lynch | 10b5-1 | EDGAR |
| 2026-06-01 | NEXTECH VI ONCOLOGY SCSP | Shareholder | 300,000 | $10.02M | 2026-06-01 | Merrill Lynch | 10b5-1 | EDGAR |
| 2026-05-12 | Daniel Bensen | Officer | 8,000 | $274.0K | 2026-05-12 | Merrill Lynch | 10b5-1 | EDGAR |
| 2026-04-13 | Daniel Bensen | Officer | 8,000 | $285.0K | 2026-04-13 | Merrill Lynch | 10b5-1 | EDGAR |
| 2026-03-26 | GILLA KAPLAN | Director | 53,172 | $2.01M | 2026-03-26 | Morgan Stanley Smith Barney LLC … | — | EDGAR |
| 2026-03-25 | GILLA KAPLAN | Director | 14,295 | $528.5K | 2026-03-25 | Morgan Stanley Smith Barney LLC … | — | EDGAR |
| 2026-03-12 | Daniel Bensen | Officer | 8,000 | $283.0K | 2026-03-12 | Merrill Lynch | 10b5-1 | EDGAR |
| 2026-02-12 | Daniel Bensen | Officer | 8,000 | $262.0K | 2026-02-12 | Merrill Lynch | 10b5-1 | EDGAR |
| 2026-01-12 | Daniel Bensen | Officer | 8,000 | $232.0K | 2026-01-12 | Merrill Lynch | 10b5-1 | EDGAR |
| 2025-12-12 | Daniel Bensen | Officer | 8,000 | $180.0K | 2025-12-12 | Merrill Lynch | — | EDGAR |
Notice value is the aggregate market value the filer states they intend to sell — not a confirmed transaction. Compare to Insider Activity (Form 4) to see which planned sales actually executed. Market-wide feed: Planned sales (Form 144).
ETF Holders
55 ETFs hold TYRA
25 shown · $129.12M total exposure · 0.03% AUM-weighted avg weight
| # | ETF | Provider | Weight | $ Exposure | ETF AUM | As Of |
|---|---|---|---|---|---|---|
| 1 | VTI Vanguard Morningstar Total Stock Market ETF | Vanguard | 0.00% | $26.9M | — | 2026-09-30 |
| 2 | XBI State Street® SPDR® S&P® Biotech ETF | SPDR (State Street) | 0.24% | $24.6M | $10.4B | 2026-10-20 |
| 3 | IWM iShares Russell 2000 ETF | iShares (BlackRock) | 0.03% | $19.2M | $75.1B | 2026-10-20 |
| 4 | VXF Vanguard Extended Market ETF | Vanguard | 0.01% | $10.8M | — | 2026-09-30 |
| 5 | IBB iShares Biotechnology ETF | iShares (BlackRock) | 0.08% | $8.3M | $11.0B | 2026-10-20 |
| 6 | IWO iShares Russell 2000 Growth ETF | iShares (BlackRock) | 0.05% | $6.9M | $13.6B | 2026-10-20 |
| 7 | VTWO Vanguard Russell 2000 ETF | Vanguard | 0.03% | $4.7M | — | 2026-09-30 |
| 8 | SCHA Schwab U.S. Small-Cap ETF | Nport | 0.02% | $3.8M | — | 2026-05-31 |
| 9 | USVM VictoryShares US Small Mid Cap Value Momentum ETF | Nport | 0.19% | $3.3M | — | 2026-06-30 |
| 10 | DFAS Dimensional US Small Cap ETF | Dimensional | 0.01% | $2.7M | — | 2026-10-20 |
| 11 | TMSL T. Rowe Price Small-Mid Cap ETF | Nport | 0.08% | $2.2M | — | 2026-06-30 |
| 12 | VHT Vanguard Health Care ETF | Vanguard | 0.01% | $2.1M | — | 2026-09-30 |
| 13 | SBIO ALPS Medical Breakthroughs ETF | Nport | 1.15% | $1.9M | — | 2026-05-31 |
| 14 | FESM Fidelity Enhanced Small Cap Core ETF | Fidelity | 0.02% | $1.5M | $6.6B | 2026-10-20 |
| 15 | DFMC Dimensional US Micro Cap ETF | Dimensional | 0.02% | $1.3M | — | 2026-10-20 |
| 16 | DWAS Invesco Dorsey Wright SmallCap Momentum ETF | Nport | 0.31% | $1.3M | — | 2026-05-31 |
| 17 | VFMO Vanguard U.S. Momentum Factor ETF | Vanguard | 0.06% | $1.1M | — | 2026-10-20 |
| 18 | FFSM Fidelity Fundamental Small-Mid Cap ETF | Nport | 0.07% | $1.1M | — | 2026-07-31 |
| 19 | LABU Direxion Daily S&P Biotech Bull 3X ETF | Direxion | 0.16% | $1.0M | — | 2026-10-21 |
| 20 | ITOT iShares Core S&P Total U.S. Stock Market ETF | iShares (BlackRock) | 0.00% | $960,330 | $97.4B | 2026-10-20 |
| 21 | VTWG Vanguard Russell 2000 Growth ETF | Vanguard | 0.05% | $870,688 | — | 2026-09-30 |
| 22 | DFAC Dimensional US Core Equity 2 ETF | Dimensional | 0.00% | $732,314 | — | 2026-10-20 |
| 23 | DCOR Dimensional US Core Equity 1 ETF | Dimensional | 0.00% | $711,660 | — | 2026-10-20 |
| 24 | CANC Tema Oncology ETF | Nport | 0.30% | $527,210 | — | 2026-05-31 |
| 25 | GSSC Goldman Sachs ActiveBeta U.S. Small Cap Equity ETF | Goldman | 0.05% | $511,422 | $1.0B | 2026-10-20 |
Fundamentals
Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.
Metrics
- Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
- Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
- Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
- Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
How to read the bars
- Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
- YoY growth — compare to the same quarter a year earlier to remove seasonality.
- Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
- Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.
TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.
Trailing P/E
—
TTM Diluted EPS
$-2.39
TTM Revenue
—
TTM Net Income
$-148.23M
TTM Op. Cash Flow
$-109.65M
Quarterly figures (12 quarters)
| Quarter | Period End | Revenue | Net Income | Diluted EPS | Op. Cash Flow |
|---|---|---|---|---|---|
| Q2 '26 | 2026-06-30 | — | $-45.56M | $-0.69 | $-31.08M |
| Q1 '26 | 2026-03-31 | — | $-39.30M | $-0.64 | $-32.57M |
| Q4 '25 | 2025-12-31 | — | $-33.51M | $-0.56 | $-23.62M |
| Q3 '25 | 2025-09-30 | — | $-29.86M | $-0.50 | $-22.38M |
| Q2 '25 | 2025-06-30 | — | $-28.10M | $-0.47 | $-23.68M |
| Q1 '25 | 2025-03-31 | — | $-28.15M | $-0.47 | $-25.46M |
| Q4 '24 | 2024-12-31 | — | $-26.94M | $-0.43 | $-19.59M |
| Q3 '24 | 2024-09-30 | — | $-22.08M | $-0.41 | $-17.90M |
| Q2 '24 | 2024-06-30 | — | $-18.70M | $-0.32 | $-10.26M |
| Q1 '24 | 2024-03-31 | — | $-18.19M | $-0.35 | $-22.03M |
| Q4 '23 | 2023-12-31 | — | $-22.83M | $-0.53 | $-13.53M |
| Q3 '23 | 2023-09-30 | — | $-21.15M | $-0.49 | $-17.14M |
Q2 2026 • period ending 2026-06-30 • filed 2026-08-04
Valuation
Ratios derived from TTM financials and the current market price, sampled daily. History chart shows how expensive the stock is today relative to its own recent past.
Price Multiples
- P/E — price / TTM earnings. Rough market rule: 10–15 value, 15–25 market, >30 growth/premium. Negative when earnings are negative.
- P/B — price / book value. Useful for financials and asset-heavy names; meaningless for asset-light software.
- P/S — price / TTM revenue. Useful when earnings are negative or noisy (early-stage growth).
- EV/EBITDA — capital-structure-neutral. <10 cheap, 10–15 reasonable, >20 rich. Good for comparing across leverage profiles.
- EV/Sales — like P/S but accounts for debt + cash. Compare within sector.
Profitability & Yields
- ROE — return on equity. >15% strong, >25% exceptional. Caution: high leverage inflates ROE.
- ROA — return on assets. Leverage-neutral; >5% solid, >10% exceptional.
- Div Yield — annual dividend / price. Compare to 10Y Treasury; sustained yield >6% often signals distress.
- FCF Yield — free cash flow / market cap. >5% is attractive; negative means burning cash.
Balance Sheet
- Debt/Equity — leverage. <1 conservative, >2 aggressive. Sector-dependent (utilities naturally high, tech low).
- Current Ratio — short-term liquidity. >1.5 comfortable, <1 raises short-term solvency flags.
Reading the history chart
- Compare current level to the 3-year band: near the high end = relatively expensive; near the low = relatively cheap.
- Multiples expanding while earnings are flat = sentiment-driven rally.
- Multiples compressing while earnings grow = value coming from fundamentals.
P/E
—
P/B
3.60
P/S
—
EV/EBITDA
—
EV/Sales
—
ROE
-41.9%
ROA
-38.7%
Div Yield
0.00%
FCF Yield
-8.62%
Debt/Equity
0.00
Current Ratio
—
Market Cap
$1.27B
as of 2026-10-21
Short Interest & Float
Regulatory short-interest reports publish on a bi-weekly settlement cadence; short-volume is reported daily by the trade-reporting facilities. Float is derived from insider-ownership filings.
Metric definitions
- Short Interest — total shares currently sold short as of the settlement date. Lags real time by ~8 business days.
- SI % of Float — short interest / free float. The key crowding metric.
- Days to Cover — short interest / avg daily volume. How many full trading days it would take shorts to buy back. High DTC + catalyst = squeeze fuel.
- Short Vol Ratio — today's short-sale volume / total volume. Intraday selling pressure proxy (not the same as short interest).
- Free Float — shares available for public trading (total shares minus insider / restricted).
- Float % — free float / shares outstanding. <50% = tightly held, more prone to squeezes.
How to read the signals
- SI % of Float < 5% — typical, no particular signal.
- 5–15% — elevated; watch for catalysts (earnings, guidance, macro).
- 15–30% — heavily shorted; tight-float names in this range have produced notable squeezes historically.
- >30% — extreme; borrow is likely expensive and squeeze risk is material.
- Days to Cover > 5 combined with high SI% amplifies squeeze potential.
History chart
- Trend matters more than level. Rapidly rising short interest often precedes negative catalysts or heavy hedging.
- A sudden drop in SI after a rally may indicate a squeeze in progress.
Short interest is reported mid-month and end-of-month; short volume is daily.
Short Interest
9.41M
SI % of Float
26.23%
Days to Cover
8.83
Short Vol Ratio
83.8%
Free Float
35.89M
Float %
60.1%
Short interest 2026-09-30 • Short volume 2026-10-21 • Float 2026-09-17